Table 2.

Detected EM clusters of Ki-67 values within subgroups of breast cancer patients defined by certain immunohistochemical phenotypes (LMA - low mitotic activity; IMA - intermediate mitotic activity; HMA - high mitotic activity). These are the results of the first stage of EM clustering

ER/PgR phenotypes			Breast cancer HER2 status
			0+		1+		2+		3+
ER + PgR+	Cancer types		Luminal A/B1						Luminal B2
	EM clusters		LMA	IMA	LMA	IMA	LMA	IMA	LMA	IMA
	Patients	n	255	83	187	46	52	11	139	26
		%	75.4	24.6	80.3	19.7	82.5	17.5	84.2	15.0
	Mean Ki-67%		9.5	39.1	11.3	39.6	13.5	38.6	19.2	56.6
	St.dev. of Ki-67		6.1	15.2	7.2	11.1	6.9	9.5	10.1	10.3
ER + PgR-	Cancer types		Luminal A/B1						Luminal B2
	EM clusters		LMA	IMA	LMA	IMA	n/a		LMA	IMA
	Patients	n	15	10	20	6	7		31	2
		%	60.0	40.0	76.9	23.1	n/a		93.9	6.1
	Mean Ki-67%		9.7	42.4	15.5	39.0			25.4	60.0
	St.dev. of Ki-67		5.4	14.8	8.6	6.0			13.3	7.1
ER-PgR-	Cancer types		triple-negative						pure HER2
	EM clusters		IMA	HMA	IMA	HMA	n/a		IMA	HMA
	Patients	n	63	43	29	11	8		111	14
		%	59.4	40.6	72.5	27.5	n/a		88.8	11.2
	Mean Ki-67%		34.0	79.0	32.3	82.7			32.4	73.2
	St.dev. of Ki-67		18.3	6.4	18.1	8.5			14.7	8.7